MOOLEC SCIENCE SA |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.24 USD | -1.59% |
|
-8.15% | -49.59% |
| 04-30 | Wall Street Poised for Cautious Day Ahead of Key Numbers, Earnings, Fed Report | MT |
| 04-30 | Top Premarket Gainers | MT |
Valuation
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 173.5 | 144.7 | 46.58 | - |
| Enterprise Value (EV) 1 | 173.5 | 144.7 | 46.58 | 46.58 |
| P/E ratio | -111 x | -2.45 x | -4.96 x | -5.17 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 160 x | 12.1 x | 7.58 x |
| EV / Revenue | - | 160 x | 12.1 x | 7.58 x |
| EV / EBITDA | - | -22,159,616 x | - | - |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 17,370 | 39,332 | 37,564 | - |
| Reference price 2 | 9.990 | 3.680 | 1.240 | 1.240 |
| Announcement Date | 12/5/22 | 10/30/23 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net sales 1 | - | 0.905 | 3.845 | 6.146 |
| EBITDA | - | -6.532 | - | - |
| EBIT 1 | - | -6.654 | -10.22 | -11.02 |
| Operating Margin | - | -735.19% | -265.9% | -179.27% |
| Earnings before Tax (EBT) 1 | - | -52.02 | -9.989 | -11.02 |
| Net income 1 | -4.527 | -51.79 | -9.711 | -9.696 |
| Net margin | - | -5,722.21% | -252.56% | -157.76% |
| EPS 2 | -0.0900 | -1.500 | -0.2500 | -0.2400 |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 12/5/22 | 10/30/23 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2023 Q4 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|
| Net sales 1 | 0.905 | 0.2521 | 0.65 | 0.992 |
| EBITDA | -0.4276 | - | - | - |
| EBIT 1 | -0.5484 | -1.793 | -3.045 | -3.118 |
| Operating Margin | -60.59% | -711.19% | -468.46% | -314.31% |
| Earnings before Tax (EBT) 1 | -2.983 | -2.019 | -3.045 | -3.118 |
| Net income 1 | -2.748 | -1.783 | -2.68 | -2.744 |
| Net margin | -303.63% | -707.42% | -412.31% | -276.61% |
| EPS 2 | -0.0300 | -0.0500 | -0.0700 | -0.0700 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 10/30/23 | 3/13/24 | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | - | - | 0.23 | 0.46 |
| Capex / Sales | - | - | 6.01% | 7.5% |
| Announcement Date | 12/5/22 | 10/30/23 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.24
USD
Average target price
6
USD
Spread / Average Target
+383.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -49.59% | 46.58M | |
| +15.59% | 3.4B | |
| -95.58% | 1.61B | |
| -2.66% | 1.58B | |
| -0.24% | 1.27B | |
| -7.92% | 1.24B | |
| -.--% | 1.23B | |
| -11.30% | 1.21B | |
| +3.70% | 1.21B | |
| 0.00% | 1.2B |
- Stock Market
- Equities
- MLEC Stock
- Financials Moolec Science SA
